Asymmetrex®’s Kinetic Stem Cell (KSC) Counting Technology is Featured in the Parent’s Guide to Cord Blood Foundation® June Newsletter
The Parent’s Guide to Cord Blood Foundation®’s monthly newsletter reports on research and development of medical treatments using blood and tissues from human umbilical cords in language that is accessible to parents of children receiving or considering such treatments. The June 14 issue of the newsletter features a graphical presentation of stem cell biotechnology company
Asymmetrex® Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine Biomanufacturing
For the past year, with R&D funding support from the Advanced Regenerative Manufacturing Institute|BioFabUSA, stem cell biotechnology company Asymmetrex has been automating and adapting its tissue stem cell counting technology for use in cell and tissue biomanufacturing. This week at ARMI’s Spring Meeting in the Millyard R&D summit, Asymmetrex is presenting the increasingly rapid and
Asymmetrex® CEO Publishes New Book on Missing Elements of U.S. COVID Science
The President and CEO of stem cell biotechnology company Asymmetrex also has training and research expertise in environmental health science and epidemiology. Cambridge Scholars Publishing recently released a book authored by him that takes a critical look at missing scientific elements in the public science supporting the COVID-19 spread narrative in the U.S. James L.
Asymmetrex Issued U.S. Trademark Registration for Business Name
On April 5, the U.S. Patent and Trademark Office issued the trademark registration “Asymmetrex,” to stem cell biotechnology company Asymmetrex, LLC. The new trademark registration brands the company’s name for supplying testing and biomanufacturing services for therapeutic tissue stem cells used in stem cell research, stem cell treatments, and drug evaluations. On April 5, 2022,
Asymmetrex Discusses Stem Cell-Specific Dosing in Veterinary Medicine with Tech Company News
Asymmetrex President and CEO James L. Sherley, M.D., Ph.D. recently contributed a chapter to a new book on Stem Cell Veterinary Science that highlights the advantages of stem cell-specific dosing for improving the effectiveness of new stem cell treatment approaches. Dr. Sherley caught up with Tech Company News to speak about this chapter and how
Asymmetrex Describes How Advancing to Stem Cell-Specific Dosing May Begin with Veterinary Stem Cell Treatments
In a new book on Stem Cell Veterinary Science, stem cell biotechnology company Asymmetrex continues its effort to educate the field of human stem cell medicine on the need for stem cell-specific dosing to improve approved stem cell treatments and FDA-authorized stem cell clinical trials. A chapter contributed to the book by Asymmetrex President and
Asymmetrex Awarded Grant from ARMI BioFabUSA to Develop Tissue Stem Cell Counting Technology for Cell Biomanufacturing
Stem cell biotechnology company Asymmetrex has been awarded a Technical Project grant from Advanced Regenerative Manufacturing Institute (ARMI) BioFabUSA. The new grant supports studies by Asymmetrex to evaluate its kinetic stem cell (KSC) counting technology as a method for determining a long-needed critical quality attribute for the biomanufacturing of potent therapeutic tissue stem cell-based products.